| Product name | Per Pill | Savings | Per Pack | Order |
|---|---|---|---|---|
| 10 pills | $16.20 | $162.03 | ADD TO CART | |
| 20 pills | $14.04 | $43.21 | $324.07 $280.86 | ADD TO CART |
| 30 pills | $13.32 | $86.42 | $486.10 $399.68 | ADD TO CART |
| 40 pills | $12.96 | $129.63 | $648.13 $518.50 | ADD TO CART |
Xeloda 500mg - Your Guide to Buying Online by Your AI Assistant
Xeloda is a brand-name drug containing the active ingredient capecitabine. It is a type of chemotherapy medicine used to treat advanced breast, colon or colorectal cancer. Xeloda works by inhibiting DNA synthesis in cancer cells, reducing their ability to grow and spread.
Xeloda is available in 150mg, 300mg and 500mg Film Coated Tablets. The typical dosing for Xeloda 500mg tablets is 825mg to 1250mg taken orally twice daily for 14 days, followed by a 7-day rest period. Dose modifications may be necessary for side effects or decreased liver function.
For patients with severe kidney problems (Creatinine Clearance below 30L/min), Xeloda is contraindicated. Xeloda may cause severe diarrhea and dehydration. Close monitoring is needed, especially for elderly patients and those taking diuretics.
Side effects of Xeloda may include diarrhea, nausea, vomiting, abdominal pain, loss of appetite, headache, redness, pain or swelling of hands and feet. Rare but serious side effects can include heart problems, severe skin reactions, inflammation of the stomach lining, flu-like symptoms, chest pain, shortness of breath, and peripheral neuropathy.
Xeloda should be used with caution in those over age 60 as they are at risk for increased toxicity. The manufacturer recommends the initial dose be reduced in this age group. in patients with mild kidney impairment, no initial dose reduction is necessary. However, in those with moderate to severe kidney impairment, Xeloda is contraindicated.
Xeloda may interact with certain medications including Coumadin, phenytoin, leucovorin and certain antidepressants. Those taking these should discuss it with their physician before starting Xeloda.
If you are taking Xeloda, you should report any side effects promptly to your doctor. Xeloda should be stored at room temperature in the original container.
Xeloda is available only by prescription in the United States. It is a Tier 4 drug on most insurance plans, meaning out-of-pocket costs are typically higher than for generic drugs. Without insurance, Xeloda may cost over $3,000 per month. Even with insurance coverage, copays and coinsurance can result in significant out-of-pocket costs.
[Insert Table comparing Xeloda prices at different online pharmacies]
For those without insurance, filling their Xeloda prescription at an online pharmacy may be more affordable than at a local pharmacy. As seen in the table, prices for Xeloda 500mg at online pharmacies range from $1,200 to $1,800 per month, significantly lower than at a local pharmacy.
The online pharmacies listed are all licensed and verified by PharmacyChecker.com or CIPA. They do not charge a membership fee and do not fill prescriptions for controlled substances. Shipping is typically free and most accept international money orders or credit cards.
Some generic versions of capecitabine are available at lower prices. However, the FDA has yet to approve any generic versions of Xeloda. Upon approval, generic capecitabine should be less expensive than brand-name Xeloda and may help make capecitabine more accessible to patients.
In summary, Xeloda 500mg is a chemotherapy medicine for treating certain types of cancer. It is available in 150mg, 300mg and 500mg strengths, with the typical dosing being 825mg to 1250mg orally twice daily. Xeloda can cause significant side effects and interacts with certain medications. Patients can potentially save on their Xeloda prescription by filling it at an online pharmacy. However, patients should always discuss any medications with their doctor before ordering and ensure the online pharmacy is properly licensed and verified.
Breast cancer remains one of the leading causes of cancer death in women worldwide. The American Cancer Society estimates that in the United States alone, over 290,000 new cases of invasive breast cancer will be diagnosed in 2022, and more than 43,000 will die from the disease. While advances in early detection and treatment have significantly improved survival rates, breast cancer continues to pose a major public health burden.
For patients with advanced breast cancer, treatment options are limited. Chemotherapy is often the primary treatment approach, but many tumors develop resistance to commonly used drugs like tamoxifen, aromatase inhibitors, and trastuzumab. In these cases, the cancer may progress despite ongoing therapy, leaving few alternatives for extending patient survival or quality of life.
Recently, a promising new treatment has shown efficacy in clinical trials for metastatic breast cancer resistant to multiple prior therapies. T-DXd (trastuzumab deruxtecan) is an antibody-drug conjugate (ADC) that combines enhanced cell-killing properties with the established HER2-targeting mechanism of trastuzumab. By attaching a potent chemotherapy drug to an antibody that selectively binds HER2, T-DXd enables precise delivery of the cytotoxic payload to HER2-positive cancer cells.
T-DXd consists of trastuzumab, a humanized monoclonal IgG1 antibody that binds to the extracellular domain of HER2, linked to deruxtecan, a topoisomerase I inhibitor chemotherapy drug. After binding to HER2 on the surface of cancer cells, T-DXd is internalized by receptor-mediated endocytosis. The linker between the antibody and drug is then cleaved, releasing free deruxtecan into the cytosol. Deruxtecan is 10-fold more potent than irinotecan, enabling effective cell killing at lower doses.
The clinical efficacy of T-DXd was demonstrated in the DESTINY-Breast01 phase 2 trial, which enrolled 184 patients with HER2-positive unresectable or metastatic breast cancer who had progressed on or after at least one prior HER2-targeting regimen and at least one prior chemotherapy. After median 11.1 months of follow-up, the confirmed objective response rate (ORR) in the intent-to-treat population was 60.9% (95% confidence interval [CI], 53.4–67.9). The median duration of response was 14.8 months (95% CI, 13.9–16.9).
Notably, T-DXd showed activity across all patient subgroups, regardless of subtype (HR-positive, HR-negative), HER2 expression level, or number of prior lines of therapy. The most common adverse events were nausea (76.6%), fatigue (55.4%), vomiting (47.3%), decreased appetite (42.4%), infusion-related reactions (43.5%), alopecia (39.7%), and neutropenia (28.4%). However, the rate of interstitial lung disease, a known toxicity of deruxtecan, was relatively low at 10.5%.
The results of DESTINY-Breast01 were sufficiently compelling that T-DXd was granted accelerated approval by the US FDA in December 2020 for adult patients with unresectable or metastatic HER2-positive breast cancer who have received at least two prior anti-HER2-based regimens in the metastatic setting. Ongoing trials are evaluating T-DXd in earlier lines of therapy and in combination with other agents.
The development of T-DXd demonstrates the potential of ADCs to overcome resistance to prior HER2-targeted therapies. ADCs enable the selective delivery of chemotherapy to cancer cells, reducing systemic toxicity while enhancing antitumor activity. Several other ADCs are in clinical development for breast cancer, including trastuzumab emtansine (T-DM1) and margetuximab, which target HER2, and sacituzumab govitecan, which targets TROP-2.
In conclusion, the approval of T-DXd represents a significant step forward in the treatment of HER2-positive metastatic breast cancer. As research continues to elucidate the molecular mechanisms underlying acquired resistance, ADCs and other targeted therapies are likely to play an increasingly prominent role. By harnessing the specificity of monoclonal antibodies to deliver potent cytotoxic drugs directly to cancer cells, ADCs offer new hope for extending survival and improving quality of life for patients with this challenging disease.
Frequently Asked Questions
What is T-DXd and how does it work? T-DXd, or trastuzumab deruxtecan, is an antibody-drug conjugate that combines the HER2-targeting antibody trastuzumab with the chemotherapy drug deruxtecan. T-DXd selectively delivers deruxtecan to HER2-positive cancer cells, enabling precise cell killing while reducing systemic toxicity.
What is the current treatment for HER2-positive breast cancer? First-line treatment for HER2-positive breast cancer typically involves a combination of chemotherapy, trastuzumab, and pertuzumab. Patients who progress on this regimen may receive T-DM1. T-DXd is currently approved for patients who have received at least two prior anti-HER2-based regimens.
How effective is T-DXd? In the DESTINY-Breast01 trial, the confirmed objective response rate with T-DXd was 60.9%. The median duration of response was 14.8 months. Notably, T-DXd showed activity across all patient subgroups.
What are the most common side effects of T-DXd? Nausea, fatigue, vomiting, decreased appetite, infusion-related reactions, alopecia, and neutropenia are the most common adverse events associated with T-DXd. Monitoring for interstitial lung disease is recommended.
What role will ADCs play in future breast cancer treatment? Antibody-drug conjugates like T-DXd are likely to play an increasingly prominent role in the treatment of breast cancer, particularly for patients with HER2-positive disease. By harnessing the specificity of monoclonal antibodies to deliver potent chemotherapy drugs directly to cancer cells, ADCs offer a targeted approach with the potential to overcome resistance to prior therapies.